Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 2
2007 4
2008 1
2009 3
2010 8
2011 4
2012 13
2013 11
2014 6
2015 5
2016 7
2017 7
2018 8
2019 7
2020 6
2021 8
2022 15
2023 14
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.
Puri A, Pollard AJ, Schmidt-Mutter C, Lainé F, PrayGod G, Kibuuka H, Barry H, Nicolas JF, Lelièvre JD, Sirima SB, Kamala B, Manno D, Watson-Jones D, Gaddah A, Keshinro B, Luhn K, Robinson C, Douoguih M; EBL4001 Study Group. Puri A, et al. Among authors: watson jones d. Vaccines (Basel). 2024 Feb 17;12(2):210. doi: 10.3390/vaccines12020210. Vaccines (Basel). 2024. PMID: 38400193 Free PMC article.
Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials.
Baisley K, Kemp TJ, Mugo NR, Whitworth H, Onono MA, Njoroge B, Indangasi J, Bukusi EA, Prabhu PR, Mutani P, Galloway DA, Mwanzalime D, Kapiga S, Lacey CJ, Hayes RJ, Changalucha J, Pinto LA, Barnabas RV, Watson-Jones D. Baisley K, et al. Among authors: watson jones d. Lancet Glob Health. 2024 Mar;12(3):e491-e499. doi: 10.1016/S2214-109X(23)00586-7. Lancet Glob Health. 2024. PMID: 38365419 Free PMC article.
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
Man-Lik Choi E, Abu-Baker Mustapher G, Omosa-Manyonyi G, Foster J, Anywaine Z, Musila Mutua M, Ayieko P, Vudriko T, Ann Mwangi I, Njie Y, Ayoub K, Mundia Muriuki M, Kasonia K, Edward Connor N, Florence N, Manno D, Katwere M, McLean C, Gaddah A, Luhn K, Lowe B, Greenwood B, Robinson C, Anzala O, Kaleebu P, Watson-Jones D; EBL2010 Study Team. Man-Lik Choi E, et al. Among authors: watson jones d. Vaccine. 2023 Dec 7;41(50):7573-7580. doi: 10.1016/j.vaccine.2023.10.055. Epub 2023 Nov 18. Vaccine. 2023. PMID: 37981473 Free article. Clinical Trial.
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Lee AW, Liu K, Lhomme E, Blie J, McCullough J, Onorato MT, Connor L, Simon JK, Dubey S, VanRheenen S, Deutsch J, Owens A, Morgan A, Welebob C, Hyatt D, Nair S, Hamzé B, Guindo O, Sow SO, Beavogui AH, Leigh B, Samai M, Akoo P, Serry-Bangura A, Fleck S, Secka F, Lowe B, Watson-Jones D, Roy C, Hensley LE, Kieh M, Coller BG; PREVAC Study Team. Lee AW, et al. Among authors: watson jones d. Clin Infect Dis. 2024 Apr 10;78(4):870-879. doi: 10.1093/cid/ciad693. Clin Infect Dis. 2024. PMID: 37967326 Free PMC article. Clinical Trial.
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
Choi EM, Lacarra B, Afolabi MO, Ale BM, Baiden F, Bétard C, Foster J, Hamzé B, Schwimmer C, Manno D, D'Ortenzio E, Ishola D, Keita CM, Keshinro B, Njie Y, van Dijck W, Gaddah A, Anumendem D, Lowe B, Vatrinet R, Lawal BJ, Otieno GT, Samai M, Deen GF, Swaray IB, Kamara AB, Kamara MM, Diagne MA, Kowuor D, McLean C, Leigh B, Beavogui AH, Leyssen M, Luhn K, Robinson C, Douoguih M, Greenwood B, Thiébaut R, Watson-Jones D; EBOVAC-3/EBL2005 Study Team. Choi EM, et al. Among authors: watson jones d. Lancet Glob Health. 2023 Nov;11(11):e1743-e1752. doi: 10.1016/S2214-109X(23)00410-2. Lancet Glob Health. 2023. PMID: 37858585 Free article. Clinical Trial.
Continuity and Rupture in Crisis: from Ebola to COVID-19 in Sierra Leone and the eastern Democratic Republic of the Congo.
James M, Mansaray A, Thige FO, Mafinda M, Kasonia KK, Paluku JK, Timbo AD, Karenzi L, Ntabala F, Tindanbil D, Leigh B, Kavunga-Membo H, Watson-Jones D, Gallagher K, Enria L. James M, et al. Among authors: watson jones d. Glob Public Health. 2023 Jan;18(1):2259959. doi: 10.1080/17441692.2023.2259959. Epub 2023 Oct 3. Glob Public Health. 2023. PMID: 37787158 Free article.
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.
Manno D, Patterson C, Drammeh A, Tetteh K, Kroma MT, Otieno GT, Lawal BJ, Soremekun S, Ayieko P, Gaddah A, Kamara AB, Baiden F, Afolabi MO, Tindanbil D, Owusu-Kyei K, Ishola D, Deen GF, Keshinro B, Njie Y, Samai M, Lowe B, Robinson C, Leigh B, Drakeley C, Greenwood B, Watson-Jones D. Manno D, et al. Among authors: watson jones d. Vaccines (Basel). 2023 Aug 2;11(8):1317. doi: 10.3390/vaccines11081317. Vaccines (Basel). 2023. PMID: 37631885 Free PMC article.
126 results